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Background: Pheochromocytoma and catecholamine-secreting paraganglioma (PPGL) are 
rare but potentially life-threatening tumors. We aimed to validate diagnosis codes for PPGL in 
the Danish National Patient Registry, the Danish National Pathology Registry, and the Danish 
Registry of Causes of Death and to create a national cohort of incident PPGL patients by link-
ing these three registries.
Patients and methods: We obtained data from the three abovementioned registries for all 
individuals registered with pheochromocytoma or catecholamine hypersecretion in Denmark 
during 1977–2016 (average population 5.30 million). We then reviewed health records for all 
individuals living in the North Denmark Region and Central Denmark Region (average popu-
lation 1.75 million) to validate the diagnosis of PPGL. We tested a number of algorithms for 
accurately identifying true cases of PPGL to maximize positive predictive values (PPVs) and 
completeness. The best algorithm was subsequently validated in an external sample.
Results: We identified 2626 individuals with a PPGL diagnosis code in Denmark, including 
787 (30.0%) in the North Denmark Region and Central Denmark Region. In this subsample, 
we retrieved the health records of 771/787 (98.0%) individuals and confirmed 198 incident 
PPGL patients (25.3%). The PPV of PPGL diagnosis codes was 21.7% in the Danish National 
Patient Registry, 50.0% in the Danish Registry of Causes of Death, and 79.5% in the Danish 
National Pathology Registry. By combining patterns of registrations in the three registries, we 
could increase the PPV to 93.1% (95% confidence interval [CI]: 88.5–96.3) and completeness 
to 88.9% (95% CI: 83.7–92.9), thus creating a national PPGL cohort of 588 patients. PPV for 
the optimal algorithm was 95.3% (95% CI: 88.5–98.7) in the external validation sample.
Conclusion: Diagnosis codes for pheochromocytoma had low PPV in several individual health 
registries. However, with a combination of registries we were able to identify a near-complete 
national cohort of PPGL patients in Denmark, as a valuable source for epidemiological research.
Keywords: registry-based research, International Classification of Diseases, ICD, Systematized 
Nomenclature of Medicine, SNOMED,  hospital register diagnoses, pathology register, cause 
of death register 
Introduction
Pheochromocytoma and catecholamine-secreting paraganglioma (PPGL) are rare but 
potentially fatal catecholamine-secreting tumors.1 During recent years, improvements 
in imaging techniques have led to increasing number of patients being incidentally 
diagnosed with adrenal tumors and evaluated for catecholamine hypersecretion.2,3 
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Whether this has led to an increase in the incidence of PPGL, 
or changes in its prognosis, remains unknown. Due to the 
rarity of the disease, large-scale studies of incidence and clini-
cal outcomes of PPGL are scarce and most previous studies 
have been limited to tertiary centers with the potential risk 
of referral bias and substantial loss to follow-up.4–7
Health care databases are a valuable source for epide-
miological research in rare diseases provided diagnoses 
are valid. Since 1967, the unique civil registration number 
in the Civil Registration System has been used to register 
all individuals living or working in Denmark with a com-
plete follow-up history of birth, addresses, migration, and 
death.8 The civil registration number enables exact linkage 
of all data routinely collected in national health registries 
in Denmark, which makes it possible to rapidly identify a 
complete nationwide cohort of individuals with a disease 
diagnosis.9,10 However, as shown in previous Danish stud-
ies on certain rare tumors10 and endocrine diseases,11,12 the 
validity of diagnosis codes of rare diseases may be relatively 
low, with positive predictive values (PPVs) of true presence 
of disease ranging from 30% to 55%. Applying algorithms 
restricting to patients hospitalized at specialized departments 
or undergoing certain treatment regimens may improve PPV 
of diagnosis codes with a limited loss of cases.10–12 To our 
knowledge, no studies have yet validated the accuracy of 
PPGL registrations. 
Therefore, we aimed to validate PPGL diagnosis codes 
and to create an algorithm that can accurately identify inci-
dent cases of PPGL in Denmark by combining data from three 
registries: the Danish National Patient Registry, the Danish 
Registry of Causes of Death, and the Danish National Pathol-
ogy Registry. This would allow us to create a nationwide, 
population-based PPGL cohort as a source for future research 
on trends in the incidence, morbidity, and mortality of PPGL.
Patients and methods 
health registries, international
Classification of Diseases (ICD), and
systematized nomenclature of
Medicine (SNOMED)
In Denmark, MDs report the primary cause of a contact at 
a Danish hospital to the Danish National Patient Registry 
for all in- and outpatient contacts with up to 20 secondary 
diagnoses.9 Likewise, for all deaths in Denmark, an MD will 
complete a death certificate and report one or more causes 
of death to the Danish Registry of Causes of Death.13 In 
both registries, diagnoses have been registered using the 
ICD 8th edition (ICD-8) until 1994, and thereafter using the 
10th edition (ICD-10).9,13 For all pathological examinations 
performed in Denmark, the pathologist registers the diagno-
sis, the origin of tissue, and performed examinations in the 
SNOMED.14 Reporting to the three registries is mandatory 
in all of Denmark. 
Generally, the coverage or completeness of the registries 
are internationally considered excellent and have not under-
gone any major structural changes in the last 20 years (see 
Table S1).9,13–16
Identification of potential PPGL cases
In order to identify all individuals with potential PPGL, we 
obtained data from the Danish Health Authority for indi-
viduals registered with at least one diagnosis code related to 
pheochromocytoma or catecholamine hypersecretion in the 
Danish National Patient Registry, Danish National Pathology 
Registry, or Danish Registry of Causes of Death (Table 1). 
The primary eligibility criterion was a PPGL diagnosis 
code at an in- or outpatient contact (as either primary, second-
ary, supplementary, or referral diagnosis code), as a cause 
of death, or as a diagnostic conclusion of a pathological 
examination. We included only patients who had their first 
PPGL diagnosis code from January 1, 1977, to December 
31, 2016, whilst living in Denmark. PPGL diagnosis codes 
included 255.29 (ICD8), D350A, E275, R825A (ICD10), 
M8700, and S29740 (SNOMED). 
Validation of PPGL diagnosis codes was limited to eli-
gible individuals living in the North Denmark Region and 
Central Denmark Region at the time of first PPGL diagnosis: 
the validation cohort. These two out of five Danish regions 
had an average population during the study period of 1.75 
million inhabitants, corresponding to 33% of the total Dan-
ish population (average population 5.30 million, calculations 
based on data from public institutions).17–20
Completeness of PPgl registrations
To assess if our eligibility criteria completely identified all 
PPGL cases, that is, if all diagnosed PPGL patients had 
been registered with a PPGL diagnosis code, we introduced 
expanded eligibility criteria. We included individuals regis-
tered with one of 31 possibly PPGL-related diagnosis codes 
in the Danish National Patient Registry between  January 
1, 1990 and  February 28, 2015 (Table 2). Validation of this 
group was restricted to individuals registered at the Depart-
ment of Endocrinology and Internal Medicine at Aarhus 
University Hospital, the largest endocrine center in Central 
Region Denmark: the expanded validation cohort.
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Table 1 Eligibility criteria
Danish National Patient Registry Danish Registry of Causes of Death Danish National 
Pathology Registry
Registration date Date of start of in- or outpatient contact Date of death or found dead Date of requisition of 
pathological examination
Type of diagnosis 
code
Diagnosis code for primary, secondary, or 
supplementary cause of contact or referral 
Diagnosis code for immediate, 
contributing, or other cause of death
Pathology code for 
diagnostic conclusion of 
pathological examination
PPGL diagnosis 
codes
iCD-8 
 255.29 Pheochromocytoma
iCD-10 
 D350a Pheochromocytoma
  E275xa Catecholamine hypersecretion
  r825a Elevated urine levels of catecholamines
snOMEDb
 ZM8700xa Pheochromocytoma
iCD-8c
  255.2 Pheochromocytoma
iCD-10c
  D350 Benign neoplasm of adrenal gland
  E275 Catecholamine hypersecretion
  r825 Elevated urine levels of drugs, 
medicaments, and biological substances
snOMED
  M8700xa 
Pheochromocytoma
  s29740 
Pheochromocytoma 
syndrome
Notes: Individuals were considered eligible if they had a PPGL diagnosis code as the specified type of diagnosis code in a registry, and the date of their first registered 
diagnosis code was between January 1, 1977, and December 31, 2017, and while they lived in Denmark. Only individuals living in the north Denmark region and Central 
Denmark Region at time of first registration were included in the validation cohort. aincluding underlying diagnosis codes. bin the Danish national Patient registry, snOMED 
diagnosis codes can only be used as optional supplementary diagnosis codes. cDiagnosis codes in the Danish registry of Causes of Death have a maximum length of four 
characters making them less detailed than in iCD-8 and iCD-10 codes in the Danish national Patient registry.
Abbreviations: ICD-8, International Classification of Diseases 8th edition; ICD-10, International Classification of Disease 10th edition; PPGL, pheochromocytoma and 
catecholamine-secreting paraganglioma; snOMED, systematized nomenclature of Medicine.
Further, we asked specialists in adrenal diseases from the 
two major endocrine centers in the validation area (Depart-
ment of Endocrinology and Internal Medicine at Aarhus Uni-
versity Hospital and Department of Endocrinology at  Aalborg 
University Hospital) to contribute with any additional PPGL 
patients who might not have been initially identified.
Thus, the final PPGL cohort in our validation area 
consisted of confirmed PPGL patients found in the valida-
tion cohort, the expanded validation cohort, or additionally 
reported by endocrine specialists (Figure 1).
Validation of PPgl diagnosis
One researcher (ALE) located and reviewed health records 
from hospitals for all individuals in the validation cohort. 
Electronic health records were reviewed, if available. Paper 
health records and/or records from hospitals outside the 
validation area were located if no electronic records existed 
or if necessary to definitively confirm or refute PPGL.
The researcher confirmed or refuted PPGL based on 
agreement among lab tests of catecholamines, vanillylman-
delic acid, and metanephrines in blood or urine; imaging stud-
ies and pathological examinations; as well as the diagnostic 
conclusion made by treating clinician as noted in health 
records. Diagnostic criteria for confirming or refuting PPGL 
are listed in Table 3.
Individuals who had ambiguous results or incomplete 
diagnostic workup were considered cases of doubt and pre-
sented to an expert panel consisting of two specialists (PLP 
and ES) in endocrinology and adrenal diseases (see Table 3 
for examples). Based on available information on performed 
tests, examinations, and imaging studies as well as medical 
history and presentation, the expert panel decided if PPGL 
was the most likely diagnosis and there was sufficient evi-
dence to confirm it. If not, PPGL was considered refuted.
For confirmed PPGL patients, we defined the date of 
clinical diagnosis as the first date of a positive pathological 
examination, an at fivefold elevated lab test for PPGL, or 
the date the treating clinician confirmed PPGL according to 
the health records.
Data were recorded in a database designed using EpiData 
Manager 4.2.0.0 (EpiData Association, Odense, Denmark).
Development of algorithm to identify 
true PPgl patients
After reviewing health records and confirming or refuting 
PPGL, we tested various algorithms to identify confirmed 
PPGL patients among all individuals fulfilling eligibility 
criteria in the North Denmark Region and Central Denmark 
Region using only their registry data. Algorithms were succes-
sively improved through several iterations to maximize PPV 
and completeness, as described in the Results section. PPV 
and completeness are defined in the Data analysis section.
Testing PPV of algorithm in external 
population
To validate the PPV result of the final optimal algorithm, we 
used the eligible external population of Region Zealand and 
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the Capital Region of Denmark (average population in study 
period 2.39 million). Here, health records were reviewed 
by a second researcher (SFJ) for a random sample of 110 
individuals, identified by the algorithm as PPGL patients, 
and diagnostic ambiguities were scrutinized by an expert 
(UFR). This was done in order to verify agreement between 
the conclusion of the algorithm based on registry data and 
researcher’s conclusion based on health records.
Data analysis
Validity of ICD-8, ICD-10, and SNOMED diagnosis codes 
was expressed in PPV, defined as the proportion of confirmed 
PPGL patients among individuals in the validation cohort 
registered with the specific diagnosis code.
Accuracy of the algorithms was expressed in terms of 
PPV and completeness. PPV was defined as the proportion of 
confirmed PPGL patients among individuals in the validation 
cohort identified by the algorithm as PPGL patients. Com-
pleteness was defined as the proportion of confirmed PPGL 
patients identified by the algorithm in the validation cohort 
among all confirmed PPGL patients in the validation area. In 
order not to overestimate completeness, the denominator also 
included confirmed PPGL patients identified by expanded 
validation criteria or reported by adrenal specialist, as they 
Table 2 Expanded eligibility criteria
Danish National Patient Registry
Registration date Date of hospital admission or outpatient contact
Type of diagnosis code Diagnosis code for primary, secondary, or supplementary cause of contact 
Possibly PPGL-related diagnosis codes iCD-8
 194.0 Malignant neoplasm of endocrine glands—suprarenal gland
 194.8 Malignant neoplasm of endocrine glands—other 
 194.9 Malignant neoplasm of endocrine glands—unspecified 
 226.0 Benign neoplasm of endocrine glands—suprarenal gland
 226.8 Benign neoplasm of endocrine glands—other
 226.9 Benign neoplasm of endocrine glands—unspecified
 239.1 neoplasm of uncertain behavior of endocrine glands and nervous system
 255.9 Other and unspecified diseases of adrenal glands
 743.4 Neurofibromatosis (von Recklinghausen)
iCD-10
 C741 Malignant neoplasm of medulla of adrenal gland
 C749 Malignant neoplasm of unspecified part of adrenal gland
 C754 Malignant neoplasm of carotid body 
 C755 Malignant neoplasm of aortic body and other paraganglia 
 D093B Carcinoma in situ of other endocrine gland
 D350 Benign neoplasm of adrenal gland
 D355 Benign neoplasm of carotid body
 D356 Benign neoplasm of aortic body and other paraganglia
 D358 Benign neoplasm, pluriglandular involvement
 D359 Benign neoplasm of endocrine gland, unspecified
 D361B Benign neoplasm of autonomic nervous system
 D441 neoplasm of uncertain behavior of adrenal gland
 D446 neoplasm of uncertain behavior of carotid body
 D447 neoplasm of uncertain behavior of aortic body and other paraganglia 
 D448a Multiple endocrine adenomatoses
 D449 Neoplasm of uncertain behavior of unspecified endocrine gland
 E278 Other specified disorders of adrenal gland
 E279 Disorder of adrenal gland, unspecified
 E348 Other specified endocrine disorders
 Q850 Neurofibromatosis (nonmalignant)
 Q858D Von hippel–lindau syndrome
 Z031W Observation for suspected malignancy in adrenal gland 
Notes: Individuals fulfilled expanded eligibility criteria if registered with a possibly PPGL-related diagnosis code as primary, secondary, or supplementary cause of contact 
in the Danish National Patient Registry, and the date of their first registered diagnosis code was between January 1, 1990, and February 28, 2015, and while they lived in 
Denmark. Only individuals living in the North Denmark Region and Central Denmark Region at time of first registration who also were registered with possibly PPGL-related 
diagnosis code at the Department of Endocrinology and internal Medicine at aarhus University hospital were included in the expanded validation cohort.
Abbreviations: ICD-8, International Classification of Diseases 8th edition; ICD-10, International Classification of Disease 10th edition; PPGL, pheochromocytoma and 
catecholamine-secreting paraganglioma.
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did not fulfill eligibility criteria and therefore could never 
be identified by the algorithm. PPV and completeness were 
reported with 95% confidence intervals (95% CIs). 
Individuals with no available health records were 
excluded from all calculations of PPV and completeness. 
Confirmed PPGL patients were excluded from all calcula-
tions if diagnosed before 1977 or while living abroad, as they 
could not be considered incident PPGL cases.
Data management and calculations were performed in 
Stata Statistical Software: release 13 (StataCorp LP, College 
Station, TX, USA) and were based on the final dataset received 
from the Danish Health Authorities on  March 22, 2017.
Ethics
The research project was approved by the Danish Data 
Protection Agency (reference number 2014-41-3198). 
Permission to review health records without individually 
informed patient consent was granted by the Danish Health 
Authorities (reference number 3-3013-1021/1) in accordance 
with Danish law.
Results
Identification of PPGL cases
A total of 2626 individuals with a PPGL diagnosis code 
were identified in all of Denmark for the period 1977–2016, 
whereof 787 (30.0%) lived in the validation area of the 
North Denmark Region and Central Denmark Region at 
time of first registered PPGL diagnosis code (Table 4): 688 
individuals were identified in the Danish National Patient 
Registry, 21 in the Danish Registry of Causes of Death, and 
214 in the Danish National Pathology Registry. A total of 
652 individuals had a PPGL diagnosis in a single registry, 
134 had a PPGL diagnosis code in two registries, and one 
in all three registries.
2,626 fulfilling eligibility criteria
787 in validation cohort 913 in expanded validation cohort
97 missing health records
812 refuted PPGL:
743 refuted by consistent
clinical workup
58 never suspected of PPGL
11 refuted by expert panelc
816 health records found
4 confirmed PPGL patients:202 confirmed PPGL patients:
9 excluded due to:
7 diagnosed before 1977
2 diagnosed outside Denmark
16 missing health records
569 refuted PPGL:
489 refuted by consistent
workup
43 never suspected of PPGL
37 refuted by expert panela
198 confirmed PPGL patients
Diagnosed in the North and Central
Regions of Denmark 1977–2016
1 confirmed PPGL patients
reported from adrenal
specialistd
150 confirmed by consistent workup
52 confirmed by expert panelb 4 confirmed by consistent workup
771 health records found
Living in validation area at time of
inclusion + possibly PPGL-related
diagnosis code at specialized department
Living in validation area at time of
inclusion
13,131 fulfilling expanded eligibility
criteriaA PPGL diagnosis code in either the Danish
National Patient Registry, Danish National
Pathology Registry or Danish Registry of 
Causes of Death first registered
01-01-1977–31-12-2016 while living in
Denmark
A possibly PPGL-related diagnosis code in
the Danish National Patient Registry first
registered 01-01-1990–28-02-2015 while
living in Denmark
Figure 1 Identification of PPGL patients in area of validation, the North Denmark Region and Central Denmark Region.
Notes: aseven cases of doubt refuted as non-secreting paragangliomas; twenty-four refuted due to weak clinical evidence despite some inconsistencies; and six refuted due to 
insufficient information to confirm PPGL. bThirty-five cases of doubt confirmed as PPGL based on pathology and clinic despite no lab tests performed (diagnosed at autopsy 
or by pathologist post-surgery); three confirmed despite no pathological examination (patient abstained from surgery or surgery not technically possibly); and fourteen 
confirmed due to strong clinical evidence despite some missing data or inconsistencies. cFive refuted as non-secreting paragangliomas; six refuted as workup were insufficient 
to confirm PPGL. dOne patient with confirmed PPGL who did not fulfill primary or expanded eligibility criteria was reported by endocrine specialist (MGR) at Department 
of Endocrinology at aalborg University hospital. 
Abbreviation: PPgl, pheochromocytoma and catecholamine-secreting paraganglioma.
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Health records were located and reviewed for 771 (98.0%) 
of the 787 patients in the validation cohort (Table 4, Figure 1). 
PPGL was confirmed in 202 patients (26.2%), including 52 
confirmed by the expert panel after further scrutinizing 89 
cases of doubt. Nine were excluded as they lived abroad at time 
of diagnosis (N = 2) or were diagnosed before 1977 (N = 7).
In the expanded validation cohort, 913 individuals with 
a possible PPGL-related diagnosis code had been registered 
at Department of Endocrinology and Internal Medicine at 
Aarhus University hospital. Health records were located 
and reviewed for 816 (89.4%) and an additional four PPGL 
patients were identified. Further, one additional PPGL patient 
was reported by the specialist at Department of Endocrinol-
ogy at Aalborg University Hospital.
In total, a final PPGL cohort of 198 confirmed incident 
PPGL patients were identified in the North Denmark Region 
and Central Denmark Region. The median difference between 
date of first-registered PPGL diagnosis code and date of 
clinical diagnosis was 0 days (IQR: clinical diagnosis 32 days 
before to 4 days after).
Table 3 PPGL diagnostic criteria for confirming or refuting PPGL
Confirmed 
1. PPgl diagnosed by pathologist 
 and lab testsa confirming PPGL or with moderate to high suspicion for PPGL
2. PPgl diagnosed by pathologist
 and lab testsa performed but report missing
 and one or more tumors identified by radio imaging in location consistent with PPGL
 and confirmed in health records by treating clinician
3. lab testsa confirming PPGL or with moderate to high suspicion for PPGL 
 and pathological examination performed but report missing
 and one or more tumors identified by radio imaging in location consistent with PPGL
 and confirmed in health records by treating clinicians
4. Case of doubt further scrutinized by expert panel, which deemed PPgl the most likely diagnosis. 
Examples on cases of doubt confirmed by expert panel:b 
 PPGL confirmed in health records by treating clinician but reports on both pathological examination and lab testsa missing.
 PPgl diagnosed by pathologist but lab testsa with low suspicion for PPgl
 PPgl diagnosed by pathologist but no lab testsa performed (eg, an incidental discovery at autopsy or after surgery on other indication)
 lab testsa confirming PPGL or with moderate to high suspicion for PPGL and PPGL confirmed in health records by treating clinician but no 
pathological examination performed (eg patient died before surgery, abstained from treatment or surgery was not technically possible)
Refuted
1. Never suspected of or evaluated for PPGL (eg, incorrect registration of wrong diagnosis code)
2. PPGL refuted by pathologist or other adrenal tumor diagnosed by pathologist (eg, adrenal cortical adenoma, metastasis)
3. lab testsa refuting PPgl
4. lab testa with low to moderate suspicion for PPgl 
 and refuted by treating clinician in health records
5. lab testa with low to moderate suspicion for PPgl 
 and radio imaging performed with no tumors located in location consistent with PPgl
6. radio imaging performed with no tumors located in location consistent with PPgl
 and refuted by treating clinician in health records
7. Pathological examination, lab tests,a or radio imaging performed but report(s) missing
 and refuted by treating clinician in health records
8. Case of doubt further scrutinized by expert panel, which deemed PPGL refuted, unlikely or with insufficient data to determine if confirmed or 
refuted.
Examples on cases of doubt refuted by expert panel:b 
 PPGL diagnosed by pathologist but lab tests refuting PPGL (eg, hormonally silent paraganglioma)
 Insufficient workup (eg, some clinical suspicion but no relevant workup or lab test with low to high suspicion for PPGL but patient abstained from 
new test, imaging or any further investigations)
 Inconsistencies in workup (eg, lab tests considered highly suspicious of PPGL but no tumors found by imaging or PPGL pathologically refuted)
Notes: aPPGL lab tests include blood and urine measurements of catecholamines, vanillylmandelic acid, and metanephrines. A single lab test elevated fivefold or more above 
reference range not caused by interfering factors (interacting drugs, trauma, critical disease, etc) was considered as confirming PPGL. Three or more lab tests consistently 
elevated 2- to 4.9-fold were considered of moderate to high suspicion for PPgl. Varying lab tests with only one or two lab tests elevated 2- to 4.9-fold or lab tests 
consistently elevated less than twofold were considered of moderate to low suspicion for PPgl. One or more lab tests consistently within reference range was considered 
as refuting PPgl. blist of examples of cases of doubt is not exhaustive.
Abbreviation: PPgl, pheochromocytoma and catecholamine-secreting paraganglioma.
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Validity of PPgl diagnosis codes
Overall, PPV of an ICD-8, ICD-10, or SNOMED diagnosis 
code for PPGL in any registry was 25.3% (95% CI: 22.3–
28.6; Table 4) for confirmed incident PPGL. ICD-8 (255.29) 
and -10 diagnosis codes (D350A, E275, and R825A) had an 
overall PPV of 21.7% (95% CI: 18.6–25.0) in the Danish 
National Patient Registry and 50.0% (95% CI: 26.0–74.0) 
in the Danish Registry of Causes of Death. 
SNOMED diagnosis codes for PPGL (M8700 and 
S29740) in the Danish National Pathology Registry had a 
higher overall PPV than the two other health registries at 
79.5% (95% CI: 73.4–84.8). Forty-three (20.3%) of 212 
individuals registered with pathological diagnosis code 
“M8700 Pheochromocytoma” did not have PPGL. Of these, 
thirty-one were refuted as incorrect entries (mainly miscoding 
of T8700 Ovary or M8720 Naevus), three as non-secreting 
paragangliomas, five due to a suspicion of PPGL later refuted 
by further examinations, and four by the expert panel as 
incorrect diagnoses of PPGL. 
algorithms for identifying PPgl patients
To identify true cases of PPGL using registry data only, 
we tested different algorithms to obtain as high a PPV and 
completeness of data as possible by combining data from 
the three registries. 
First, we found that if a person was registered with a 
PPGL diagnosis code in at least two of the three registries, a 
PPV of 97.7% (95% CI: 93.4–99.5) was achieved (Table 5). 
However, the completeness was rather low as this algorithm 
only identified 127 or 64.1% (95% CI: 57.0–70.8) of the 
198 confirmed PPGL patients. Secondly, we found a PPV 
of 93.6% (95% CI: 88.9–96.8) for PPGL diagnosis codes 
registered in the Danish National Pathology Registry if the 
pathological examination had been performed on a relevant 
tissue or if the patient also had a surgical procedure code 
for adrenal surgery (086, 088, 090, and KBC) in the Danish 
National Patient Registry. We defined the examined tissue 
to be relevant if the pathological examination was registered 
as an autopsy (material code 31) or with a SNOMED code 
for either the adrenal glands (T93 and ÆF4330), paragan-
glioma (T94, T95, M868, and M869), or the body as a whole 
(T0010). 
Combined PPGL diagnosis codes in two registries or 
PPGL pathologically confirmed in a relevant tissue had a 
PPV of 93.9% (95% CI: 89.3–96.9) and a completeness of 
85.4% (95% CI: 79.6 –90.0). However, several patients who 
Table 4 PPgl registrations and validity of diagnosis codes
Diagnosis code Individuals 
in Denmark 
with diagnosis 
code
Individuals in 
validation area 
with diagnosis code 
(percentage of total)
Health 
records 
available
PPGL 
confirmede
 PPV (95% CI)e
Danish national Patient registry   
 255.29 Pheochromocytomaa 721 263 (36.5%) 249 49 20.2% (15.4–25.9)
 D350a Pheochromocytomab 892 268 (30.0%) 268 82 30.8% (25.3–36.8)
 E275x Catecholamine hypersecretionb,d 877 195 (22.2%) 194 46 23.7% (17.9–30.3)
 r825a Elevated urine levels of catecholaminesb 2 1 (50.0%) 1 0 0.0% (0.0–97.5)
 ZM8700x Pheochromocytomac,d 24 8 (33.3%) 8 5 71.4% (29.0–96.3)
 Total individuals in registry 2323 688 (29.6%) 673 144 21.7% (18.6–25.0)
Danish registry of Causes of Death   
 255.2 Pheochromocytomaa 31 9 (29.0%) 8 6 100.0% (54.1–100.0)
 D350: Benign neoplasm of adrenal glandb 63 11 (17.5%) 11 3 27.3% (6.0–61.0)
 E275:  adrenomedullary hyperfunctionb 1 1 (100.0%) 1 0 0.0% (0.0–97.5)
  r825: Elevated urine levels of drugs, medicine 
or biological substancesb
0 – – – –
 Total individuals in registry 95 21 (22.1%) 20 9 50.0% (26.0–74.0)
The Danish national Pathology registry   
 M8700x: Pheochromocytomac,d 630 214 (34.0%) 212 167 79.5% (73.4–84.8)
 s29740: Pheochromocytoma syndromec 5 2 (40.0%) 2 2 100.0% (15.8–100.0)
 Total individuals in registry 630 214 (34.0%) 212 167 79.5% (73.4–84.8)
Total individuals in all registries 2626 787 (30.0%) 771 193 25.3% (22.3–28.6)
Notes: Each person can be included in the table with more than one diagnosis code and in more than one registry. aInternational Classification of Diseases 8th edition. 
bInternational Classification of Disease 10th edition. csystematized nomenclature of medicine. dincluding underlying codes. eNine confirmed PPGL patients were excluded as 
they were diagnosed before 1977 or while living outside Denmark.
Abbreviations: CI, confidence interval; PPGL, pheochromocytoma and catecholamine-secreting paraganglioma; PPV, positive predictive value.
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had died prior to surgery or prior to definitive diagnosis were 
not identified.
Thirdly, we found that the ICD-8 diagnosis code 255.2 
in the Danish Registry of Causes of Death had a PPV of 
100.0% (95% CI: 54.1–100.0). The ICD-10 codes had low 
PPV in the Danish Registry of Causes of Death and were not 
included in the algorithm.
Finally, a PPGL diagnosis code in the Danish National 
Patient Registry less than 30 days before date of death iden-
tified five PPGL patients who had not been included by the 
above-mentioned algorithms.
Other attempts to increase the PPV of registrations in 
the Danish National Patient Registry included restricting to 
individuals registered at specialized endocrine departments 
or with at least two or three separate in- or outpatient contacts 
with PPGL diagnosis codes. This increased PPV but did not 
contribute with more confirmed PPGL patients and was not 
included in the final algorithm (Table S2).
The final algorithm, combining the four algorithms 
above, had a PPV of 93.1% (95%CI: 88.5–96.3). Of the 569 
individuals with a PPGL diagnosis code for whom PPGL 
was refuted, only 13 (2.3%) were falsely identified by the 
final algorithm as PPGL patients. It identified 176 of the 198 
confirmed PPGL patients in our validation area, resulting in 
a completeness of 88.9% (95% CI: 83.7–92.9). There were 
no significant differences in sex, age at diagnosis, or year of 
diagnosis between PPGL patients who were identified by the 
algorithm and patients who were missed (data not presented). 
Subsequently, we applied the final algorithm to the exter-
nal population of the remaining three regions. The algorithm 
identified 394 individuals as PPGL patients, of whom we 
sampled 110 from Region Zealand and the Capital Region 
of Denmark for external validation of the algorithm. Health 
records were located for 86 (78.2%), and 82 patients were 
confirmed as PPGL patients, resulting in an external PPV for 
incident PPGL of 95.3% (95% CI: 88.5–98.7). Thus, with 
198 PPGL patients from our validation area and 394 PPGL 
patients identified by the algorithm in the other regions minus 
four for whom PPGL were refuted, we identified a national 
cohort of 588 PPGL patients.
Discussion
In this population-based study, we have validated ICD-8, 
ICD-10, and SNOMED diagnosis codes for PPGL. We found 
that overall PPV was low but varied considerably between 
diagnosis codes and health registries. However, based on 
data from 198 confirmed PPGL patients, we developed an 
algorithm, which identified a national cohort of incident 
PPGL cases in the registries with high PPV as well as high 
completeness.
We have no previous studies on validity of PPGL diagno-
sis codes to compare with, but our results on PPV of diagnosis 
codes in the Danish National Patient Registry are comparable 
to similar studies on other rare diseases, which found overall 
PPV ranging from 34% to 55%.10–12 Unsurprisingly, we found 
that records in the Danish National Pathology Registry had 
the highest PPV when comparing the three health registries, 
as pathologists are trained in using the SNOMED system 
and are responsible for registering their own examinations. 
In addition, the diagnosis code is routinely updated if new 
tests on or reexaminations of the tissue leads to another diag-
nosis.14 In contrast, diagnosis codes in the two other registries 
Table 5 Algorithms for identifying confirmed PPGL patients
Algorithms PPV % (95% CI) FP,
N
Completeness
% (95% CI)
FN,
N
registered with any PPgl diagnosis codes in more than one registrya  97.7% (93.4–99.5) 3  64.1% (57.0–70.8) 71
registered in the Danish national Pathology registry with a PPgl diagnosisb code +
the examination was performed on a relevant tissuec or the patient is registered with 
a surgical procedure code for adrenal surgeryd in the Danish national Patient registry
 93.6% (88.9–96.8) 11  81.8% (75.7–86.9) 36
registered with the iCD-8 diagnosis code 255.2 for pheochromocytoma in the Danish 
registry of Causes of Death
 100.0% (54.1–100.0) 0  3.0% (1.1–6.5) 192
registered with a diagnosis code for pheochromocytoma or catecholamine 
hypersecretion in the Danish national Patient registry less than 30 days before date 
of death
 83.3% (51.6–97.9) 2  5.1% (2.4–9.1) 188
all algorithms combined  93.1% (88.5–96.3) 13  88.9% (83.7–92.9) 22
Notes: asee Table 1 for included registries and diagnosis codes. bM8700 or s29740, including underlying codes. cRelevant tissue defined as material code for autopsy 
“31: deceased body”, or with snOMED diagnosis codes, including underlying codes: topography codes “T0010: body as a whole”, “T93: adrenal gland” and “T94-95: 
paraganglioma”, morphology codes “M868-869: paraganglioma” or etiology code “ÆF4330: originated from adrenal gland”. dProcedure codes for adrenal surgery, including 
underlying codes: “086: explorative incision on adrenal gland”, “088: biopsy of adrenal gland”, “090: adrenalectomy”, and “KBC: surgery on adrenal gland”.
Abbreviations: CI, confidence interval; FP, false positive; FN, false negative; ICD-8, International Classification of Diseases 8th edition; PPGL, pheochromocytoma and 
catecholamine-secreting paraganglioma; PPV, positive predictive value.
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are often registered by MDs with only a limited knowledge of 
the patient and might be registered as a probable, suspected, 
or even a refuted diagnosis.9,13,16
It is difficult to assess the completeness of the registries, 
as we do not know how many PPGL patients we missed in 
our validation area, whether undiagnosed or diagnosed but not 
registered. However, we have included three complementary 
registries, found health records for almost all in the validation 
cohort, and when we examined other possibly PPGL-related 
diagnosis codes, we only found a few PPGL patients. There-
fore, we believe that we have identified the vast majority of 
the diagnosed PPGL patients in the validation area. Based on 
our results, we conclude that while most PPGL patients had a 
PPGL diagnosis code in the Danish National Pathology Regis-
try or the Danish National Patient Registry, no single registry 
was sufficient to identify a complete cohort of PPGL patients.
The final algorithm identified PPGL patients with a high 
PPV, which we also validated in an external sample. This is 
important for future studies on differences in comorbidity 
and cause-specific mortality for PPGL patients compared 
to the background population. A high PPV minimizes the 
risk of misclassification bias, which could otherwise bias 
results both toward and away from the null hypothesis. 
Again, assuming we found most diagnosed incident PPGL 
patients in the validation area, the algorithm also had a high 
completeness, meaning it also has the potential for monitor-
ing changes in incidence and prevalence of PPGL over time. 
However, some limitations of the algorithm must be consid-
ered. First, even though accuracy of the algorithm did not 
change during our study period, future changes in registries 
or coding procedures could both positively and negatively 
affect PPV and completeness. Secondly, we did not evaluate 
the completeness of the algorithm in an external population 
as we did with the PPV of the algorithm. However, giving 
the uniform organization of the health care system across all 
Danish regions, including the health registries, we assume 
that our results can be generalized to the rest of Denmark. 
Lastly, even though completeness of the algorithm was high, 
it may miss PPGL patients with a nonclassical clinical course, 
for example, patients deemed too old or fragile to undergo 
surgery who therefore might not have been registered in the 
Danish National Pathology Registry. While this group is quite 
small and therefore of little concern in regard to incidence and 
prevalence, it might be of importance if, for example, study-
ing mortality of PPGL patients who do not undergo surgery.
The algorithm was created using Danish health reg-
istries, which, together with health registries in the other 
Scandinavian countries, are internationally considered  to 
be comprehensive and have a high data quality.9 Thus, our 
results cannot readily be extrapolated to countries with less 
comprehensive health registries.
Conclusion
Diagnosis codes for pheochromocytoma and catecholamine 
hypersecretion had a low PPV in several individual health 
registries in Denmark. However, with a combination of reg-
istries, we could identify a near-complete national cohort of 
incident PPGL patients in Denmark as a valuable source for 
future epidemiological research.
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Supplementary Materials
Table S1 important changes in health registries
Danish National Patient Registry Danish Registry of Causes of Death Danish National Pathology Registry
Contents administrative and clinical information 
for all hospital contacts, including 
dates, diagnosis codes, and performed 
procedures.
Diagnoses are registered by the physician 
discharging the patient. Procedures are 
registered by the responsible surgeon. 
Time and cause(s) of death for every 
Danish decedent.
Cause(s) of death are registered by the 
physician with most accurate knowledge 
of patient either hospital physician or 
practitioner. if autopsy is performed, the 
pathologist adds his or her findings.
information on pathological examinations 
including tests performed, free text 
description of examination and snOMED 
codes on topography and diagnostic 
conclusions.
Data are reported by requisitioning 
department and pathologist(s) performing 
examination. 
Coverage somatic hospital admissions discharged 
after  January 1, 1977, psychiatric 
admissions discharged after  January 1, 
1995, and still-active admissions from 
2015, and onward.
Outpatient contacts ending in or active 
since 1995.
Emergency department contacts since 
1995.  
Danish residents dying while residing in 
Denmark since 1970. 
Danish residents dying in greenland and 
the Faroe islands and greenlanders and 
Faroese living in Denmark were included 
in 1983.
includes incomplete data from some public 
pathology departments back to 1970 with 
national coverage from 1997.
registration became mandatory for private 
practicing pathologist in 2005.
Important 
changes in 
data
Diagnoses registered using Danish 
adaptions of iCD-8 1977–1993 and iCD-
10 1994–now. 
Changes in registration of surgical 
procedures in 1981, 1989, and 1996, 
currently using Danish adaptation 
of Nordic Classification of Surgical 
Procedures.
has been basis for reimbursing 
departments and hospitals since 2000. 
Diagnoses registered using Danish 
adaptions of iCD-8 1977–1993 and iCD-
10 1994–now. 
Data were submitted by paper 
death certificates in 1970–2006 and 
electronically since 2007.
In the 1970s, 75% of patients dying at 
hospitals were autopsied compared to 
less than 20% today.13 
Data were submitted by different computer-
based systems and with varying data 
recorded 1970–1996. in 1997 a national 
standard for which data to register were 
defined. In 1999 a single national online tool 
for registering data were introduced.
Note: Data from references 9 and 13 to 16.
Abbreviations: ICD-8, International Classification of Diseases 8th edition; ICD-10, International Classification of Disease 10th edition; SNOMED, Systematized 
nomenclature of Medicine.
Table S2 PPV and completeness of diagnosis codes in Danish national Patient registry by number of in- or outpatient contacts
Diagnosis codes PPV or 
completeness
At least one 
contact
At least two 
contacts
At least three 
contacts
255.29, D350a, E275x a, r825a, or ZM8700xa as primary, 
secondary, supplementary, or referral diagnosis code
PPV
Completeness
 21.7% (18.6–25.0) 
 72.7% (66.0–78.8)
 54.5% (47.7–61.3) 
 60.6% (53.4–67.5)
 72.3% (64.0–79.6) 
 50.0% (42.8–57.2)
255.29, D350a, or ZM8700xa as primary, secondary, 
supplementary, or referral diagnosis code
PPV
Completeness
 24.9% (21.1–28.9) 
 63.1% (56.0–69.9)
 56.4% (48.6–63.9) 
 49.0% (41.8–56.2)
 75.7% (66.8–83.2) 
 43.9% (36.9–51.2)
255.29, D350a, or ZM8700xa
without referral diagnosis codes
PPV
Completeness
 27.0% (23.0–31.3) 
 62.1% (55.0–68.9)
 59.3% (51.3–66.9) 
 48.5% (41.3–55.7)
 76.3% (67.4–83.8) 
 43.9% (36.9–51.2)
255.29, D350a, or ZM8700xa
as primary diagnosis codes
PPV
Completeness
 47.7% (41.3–54.2) 
 58.1% (50.9–65.0)
 75.9% (67.0–83.3) 
 44.4% (37.4–51.7)
 85.9% (76.6–92.5) 
 36.9% (30.1–44.0)
255.29, D350a, or ZM8700xa
at any endocrine departmentsb
PPV
Completeness
 42.4% (35.6–49.4) 
 44.9% (37.9–52.2)
 77.3% (66.2–86.2) 
 29.3% (23.1–36.2)
 82.1% (66.5–92.5) 
 16.2% (11.3–22.0)
255.29, D350a, or ZM8700xa
at tertiary endocrine departmentsb
PPV
Completeness
 46.3% (39.1–53.7) 
 44.4% (37.4–51.7)
 77.0% (65.8–86.0) 
 28.8% (22.6–35.6)
 82.1% (66.5–92.5) 
 16.2% (11.3–22.0)
Notes: aincluding underlying codes. bnot including referral diagnosis codes to endocrine departments. 
Abbreviations: PPV, positive predictive value.
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